- Investing Ideas
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
7
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
7 companies
Hugel
Market Cap: ₩2.6t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩239,500.00
7D
1.5%
1Y
-32.5%
Oscotec
Market Cap: ₩1.2t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩30,150.00
7D
-3.4%
1Y
-13.0%
DongKook Pharmaceutical
Market Cap: ₩870.2b
Produces and sells pharmaceutical products in South Korea and internationally.
A086450
₩19,290.00
7D
5.3%
1Y
3.4%
Medy-Tox
Market Cap: ₩466.7b
Operates as a biopharmaceutical company in South Korea.
A086900
₩71,600.00
7D
0.7%
1Y
-55.9%
Daihan PharmaceuticalLtd
Market Cap: ₩150.8b
Engages in the manufacture and sale of therapeutic drugs in South Korea.
A023910
₩25,650.00
7D
0.6%
1Y
-23.9%
Macrogen
Market Cap: ₩127.2b
Provides precision medicine and bio-engineering healthcare services in Korea and internationally.
A038290
₩11,730.00
7D
0.3%
1Y
-26.3%
DreamCIS
Market Cap: ₩74.5b
Operates as a clinical research organization in South Korea, Europe, China, Asia Pacific, the United States, and Canada.
A223250
₩3,030.00
7D
-1.3%
1Y
-16.4%